Vardenafil Formulation for Sustained Plasma Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vardenafil's low bioavailability and rapid plasma concentration decrease after oral administration lead to variable therapeutic effects and require precise timing for administration, while existing mouth-disintegrating formulations fail to enhance bioavailability or maintain plasma levels.
Innovation Solution
A vardenafil formulation that rapidly disintegrates in the mouth, with at least 80% of the vardenafil dose dissolving in 10 ml of physiological saline at 25°C and a release rate of at least 70% within 5 minutes in 900 ml of saline, using vardenafil salts and incorporating disintegrants like sugar alcohols and surfactants, optimized for administration by dissolving in the oral cavity before swallowing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If vardenafil is administered as a conventional oral tablet, then the formulation is easy to manufacture and swallow, but the bioavailability is low (about 14%) and plasma concentration decreases rapidly after 1 hour
Solution Approach 1:
The patent changes the physical and chemical parameters of vardenafil by converting it to different salt forms (hydrochloride, mesilate, sulfate) and controlling its particle size (D90 ≤ 5 μm, preferably ≤ 2 μm). These parameter changes dramatically improve dissolution rate and bioavailability while maintaining ease of manufacture through standard pharmaceutical processing techniques.
Solution Approach 2:
The patent creates a composite formulation combining ultra-fine vardenafil salt particles with specific excipients including disintegrants (croscarmellose sodium, sodium starch glycolate), surfactants (sodium lauryl sulfate, polysorbate 80), and fillers (microcrystalline cellulose, mannitol). This composite material achieves both high bioavailability and manufacturability.
2Device complexity
If vardenafil is administered as a conventional oral tablet, then the formulation structure is simple, but the plasma concentration variability between individuals is high
Solution Approach 1:
By controlling particle size parameters (D90 ≤ 5 μm) and salt form selection, the patent reduces dissolution rate variability between tablets, which directly reduces plasma concentration variability between individuals. The standardized manufacturing process for ultra-fine particles ensures consistent performance.
Solution Approach 2:
The patent introduces surfactants (sodium lauryl sulfate, polysorbate 80) as intermediaries that mediate between the hydrophobic vardenafil molecules and the aqueous gastrointestinal environment. These intermediaries ensure consistent dissolution and absorption, reducing inter-individual variability.
3Reliability
If the dosage is increased to compensate for low bioavailability, then the therapeutic effect is achieved, but the risk of side effects increases
Solution Approach 1:
By changing the dissolution rate parameter through ultra-fine particle size and salt selection, the patent enables achievement of therapeutic plasma concentrations with lower doses (5-10 mg instead of 20-40 mg), thereby reducing the risk of dose-dependent side effects while maintaining therapeutic efficacy.
4Reliability
If patients time administration carefully to benefit from high plasma concentrations, then the therapeutic activity is optimized, but the ease of operation is reduced
Solution Approach 1:
The patent performs preliminary action by formulating vardenafil with extended-release characteristics through the specific composite material composition. This preliminary formulation design ensures that plasma concentrations are maintained over an extended period, eliminating the need for patients to time their administration carefully and greatly simplifying ease of operation.
5Ease of operation
If mouth-disintegrating formulations are used, then the ease of operation is improved, but the bioavailability is not increased and plasma concentrations decrease rapidly
Solution Approach 1:
The patent applies parameter changes by using ultra-fine particle size (D90 ≤ 5 μm) and specific salt forms that maintain high dissolution rates even in the mouth-disintegrating formulation. This ensures that the rapid disintegration does not compromise bioavailability, unlike conventional formulations where disintegration leads to rapid dissolution and subsequent rapid elimination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significantly higher bioavailability and sustained plasma concentrations, maintaining elevated levels several hours after administration, compared to conventional tablets, with relative bioavailability up to 149.6% and prolonged pharmacokinetic activity.
Implementation Method 1
at least 80% of the vardenafil dose in the substance form employed, for example the salt or the mixture with an acid, dissolves at 25° C. in 10 ml of physiological saline
Implementation Method 2
incorporating disintegrants like sugar alcohols and surfactants
Data Source
AI summary
The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.